|
Jul 18
|
Regeneron Stock Plunges 22.6% YTD: Should You Buy, Sell or Hold?
|
|
Jul 17
|
3 Reasons to Avoid REGN and 1 Stock to Buy Instead
|
|
Jul 16
|
UBS Raises Regeneron (REGN) Price Target, Maintains Neutral Rating
|
|
Jul 15
|
Lilly’s Zepbound Faces a Potential Weight-Loss Rival. It’s Made by a Chinese Biotech.
|
|
Jul 15
|
Health Canada extends Evkeeza approval for children with HoFH
|
|
Jul 15
|
1 Healthcare Stock on Our Buy List and 2 to Brush Off
|
|
Jul 14
|
Ascites Market Analysis and Forecasts Report 2025-2035 | Market Surges Amid Rising Liver Disease and Cancer Prevalence
|
|
Jul 14
|
Myopic Macular Degeneration Market Analysis and Forecast Report 2025-2035 | Advancements in Anti-VEGF Therapies Driving Progress in Treatments
|
|
Jul 14
|
Wet Age-Related Macular Degeneration (Wet AMD) Market Analysis Report 2025-2035 | Long-Acting Therapies, AI Diagnostics, and Personalized Medicine Set to Redefine the Future Landscape
|
|
Jul 11
|
Regeneron (REGN) Scores FDA Approval, JP Morgan Reaffirms $800 Price Target
|
|
Jul 10
|
Biologic Competition, Payer Pressures, and Gene Therapy Momentum Define a Pivotal Moment in nAMD and DME Management, According to Spherix Global Insights
|
|
Jul 10
|
MAIA Biotechnology doses first patient in expansion of Phase II lung cancer trial
|
|
Jul 9
|
MAIA Biotechnology Announces First Patient Dosed in Expansion of Phase 2 Trial for Ateganosine in Advanced Non-Small Cell Lung Cancer
|
|
Jul 8
|
Regeneron’s Blockbuster Dupixent Faces a New Rival
|
|
Jul 8
|
The Next Moderna? This Clinical-Stage Biotech Has Breakout Potential.
|
|
Jul 8
|
Regeneron’s Lynozyfic Gains Accelerated FDA Approval for Multiple Myeloma
|
|
Jul 7
|
Apogee Dives. But It Could Eventually Rival Sanofi's Biggest Moneymaker.
|
|
Jul 7
|
Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs
|
|
Jul 7
|
Intellia Gains 29.8% in a Month: How Should You Play the Stock?
|
|
Jul 5
|
2 Beaten-Down Stocks to Buy and Hold
|